(S)-6-(2-hydroxy-2-methyl-propyl)-3-{(S)-1-[4-(1-methyl-2-oxo-1,2-dihydro-pyridin-4-yl)-phenyl]-ethyl}-6-phenyl-[1,3]oxazinan-2-one
| 中文名称 | (S)-6-(2-hydroxy-2-methyl-propyl)-3-{(S)-1-[4-(1-methyl-2-oxo-1,2-dihydro-pyridin-4-yl)-phenyl]-ethyl}-6-phenyl-[1,3]oxazinan-2-one |
|---|---|
| 中文同义词 | 化合物 T26794;化合物 BI-135585 |
| 英文名称 | (S)-6-(2-hydroxy-2-methyl-propyl)-3-{(S)-1-[4-(1-methyl-2-oxo-1,2-dihydro-pyridin-4-yl)-phenyl]-ethyl}-6-phenyl-[1,3]oxazinan-2-one |
| 英文同义词 | (S)-6-(2-hydroxy-2-methyl-propyl)-3-{(S)-1-[4-(1-methyl-2-oxo-1,2-dihydro-pyridin-4-yl)-phenyl]-ethyl}-6-phenyl-[1,3]oxazinan-2-one;2H-1,3-Oxazin-2-one, 3-[(1S)-1-[4-(1,2-dihydro-1-methyl-2-oxo-4-pyridinyl)phenyl]ethyl]tetrahydro-6-(2-hydroxy-2-methylpropyl)-6-phenyl-, (6S)-;BI 135585,BI135585 |
| CAS号 | 1114561-85-1 |
| 分子式 | C28H32N2O4 |
| 分子量 | 460.56 |
| EINECS号 | |
| 相关类别 | 制剂-抑制剂 |
| Mol文件 | 1114561-85-1.mol |
| 结构式 | ![(S)-6-(2-hydroxy-2-methyl-propyl)-3-{(S)-1-[4-(1-methyl-2-oxo-1,2-dihydro-pyridin-4-yl)-phenyl]-ethyl}-6-phenyl-[1,3]oxazinan-2-one 结构式](CAS/20180703/GIF/1114561-85-1.gif) |
(S)-6-(2-hydroxy-2-methyl-propyl)-3-{(S)-1-[4-(1-methyl-2-oxo-1,2-dihydro-pyridin-4-yl)-phenyl]-ethyl}-6-phenyl-[1,3]oxazinan-2-one 性质
| 溶解度 | DMSO:0.0(最大浓度 mg/mL);0.0(最大浓度 mM) |
|---|
(S)-6-(2-hydroxy-2-methyl-propyl)-3-{(S)-1-[4-(1-methyl-2-oxo-1,2-dihydro-pyridin-4-yl)-phenyl]-ethyl}-6-phenyl-[1,3]oxazinan-2-one 用途与合成方法
BI-135585 是一种有效、选择性和具有口服活性的 11β-羟基类固醇脱氢酶 1 (11β-HSD1) 抑制剂，IC50 为 13 nM。BI-135585 的选择性是其他羟基类固醇脱氢酶的 1000 倍以上。BI-135585 可用于 2 型糖尿病的研究。